Charles Riv­er’s CD­MO busi­ness slows; Lil­ly boosts GLP-1 ca­pac­i­ty; Te­va’s Is­rael sites 'u­naf­fect­ed'

End­points News delved in­to an­oth­er week of in­vestor calls to gath­er key bio­phar­ma man­u­fac­tur­ing up­dates. We found that Charles Riv­er is look­ing to in­crease its man­u­fac­tur­ing cus­tomers with com­mer­cial as­sets, and Eli Lil­ly is aim­ing to fur­ther bol­ster man­u­fac­tur­ing for its weight loss drug.

Charles Riv­er is look­ing to im­prove its CD­MO busi­ness af­ter this seg­ment’s rev­enue de­creased by 7.3% in the third quar­ter, down to $175.7 mil­lion from $189.6 mil­lion re­port­ed in the same time last year. In to­tal, the man­u­fac­tur­ing di­vi­sion made $596.5 mil­lion in the first three quar­ters of 2023, down from $577.5 mil­lion last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER